An exploratory study of the safety, tolerability, pharmacokinetics and potential effectiveness of AVI-4020 injection in patients presenting with presumptive acute neuroinvasive West Nile virus (WNV) disease
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2012
At a glance
- Drugs AVI 4020 (Primary)
- Indications West Nile virus infections
- Focus Adverse reactions; Pharmacokinetics
- 02 Aug 2012 Lead trial centre (Sarepta Therapeutics) added as reported by ClinicalTrials.gov record.
- 03 Oct 2005 New trial record.